Literature DB >> 10066052

Low levels of IgG antibodies against pneumocystis carinii among HIV-infected patients.

A L Laursen1, P L Andersen.   

Abstract

IgG antibodies against Pneumocystis carinii (P. carinii) were detected by an ELISA method using urea-extracted material from human and rat P. carinii as the antigen. Carbohydrate formed a major part of the antigen responsible for reactivity in the ELISA assay, since periodate treatment reduced the reactivity of most sera tested. Cross-reactivity between human and rat P. carinii was detected. However, human serum recognized antigens specific for human P. carinii. With the ELISA method IgG antibody levels were compared between blood donors (n = 40), asymptomatic HIV-antibody positive patients (n = 30) and AIDS patients with (n=22) and without previous P. carinii pneumonia (PCP) (n=21). HIV-infected patients had significantly lower antibody reactivity against the microorganism compared with blood donors. Among HIV-antibody positive patients the highest antibody reactivity was seen in PCP patients. The antibody response to PCP was impaired, since an equal number of patients had an increase and a decrease in antibody reactivity. In conclusion, carbohydrate formed an important part of the P. carinii immunogenic antigen. Cross-reactivity between rat and human P. carinii was demonstrated, but reactivity was somewhat lower using antigen from rats. The antibody level was lower in HIV-infected patients and the ability to mount an antibody response to the infection was impaired, suggesting that the poor antibody response may contribute to the liability of HIV-infected patients to have PCP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10066052     DOI: 10.1080/00365549850161511

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

1.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

2.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

3.  Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection.

Authors:  Peter D Walzer; Kpandja Djawe; Linda Levin; Kieran R Daly; Judith Koch; Lawrence Kingsley; Mallory Witt; Elizabeth T Golub; Jay H Bream; Babafemi Taiwo; Alison Morris
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

4.  Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.

Authors:  Kpandja Djawe; Laurence Huang; Kieran R Daly; Linda Levin; Judy Koch; Alexandra Schwartzman; Serena Fong; Brenna Roth; Anuradha Subramanian; Katherine Grieco; Leah Jarlsberg; Peter D Walzer
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

5.  Antibody response to Pneumocystis jirovecii major surface glycoprotein.

Authors:  Kieran R Daly; Laurence Huang; Alison Morris; Judy Koch; Kristina Crothers; Linda Levin; Shary Eiser; Supriya Satwah; Patricia Zucchi; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

6.  Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Authors:  Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

7.  Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Authors:  Kieran R Daly; Judy Koch; Linda Levin; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.